A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

123 adults with type 1 diabetes were randomly assigned to technosphere insulin plus insulin degludec (Tresiba, Novo Nordisk) with use of a Dexcom G7 continuous glucose monitor, or usual care with ...

The approval covers all 27 European Union member states. Tresiba (insulin degludec) is a once-daily new-generation based insulin analogue with an ultra-long duration of action. Ryzodeg (insulin ...

Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

by 21% and Tresiba (insulin degludec) an ultra long-acting insulin, by 28%. The prices that patients will pay depends on their insurance scheme, with most paying a fixed co-payment for their ...

Otherwise known as an artificial pancreas or closed-loop system, an automated insulin delivery (AID) system is a technology ...

Long-acting insulin helps people with diabetes maintain normal blood sugar levels throughout the day. Unlike short-acting insulin, it never peaks, keeping an even sugar level in your blood.

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar lowering effect. Rapid acting insulin called insulin aspart - this lowers your ...

Ryzodeg ® 70/30 contains two types of insulin: Basal insulin called insulin degludec - this has a long blood sugar level lowering effect. Rapid-acting insulin called insulin aspart - this lowers ...